Actively Recruiting
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
Led by Nottingham University Hospitals NHS Trust · Updated on 2025-04-08
12
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose. The most common cause of HLH in adults is lymphoma (blood cancer). Outcomes for adults with HLH and cancer are serious, and most die after days or weeks because they have been diagnosed or treated too late. It is likely that many cases where patients died of HLH with no underlying cause actually had cancer. Recently it has been found that patients with certain types of lymphoma have DNA which comes directly from their cancer (circulating tumour DNA; ctDNA). Aggressive lymphomas release a lot of ctDNA which can be detected in the blood of patients. This study will look for ctDNA in patients with HLH, and see if it is possible to use it to diagnose lymphoma earlier. Patients will provide a small additional blood sample for analysis. Diagnosing lymphoma more rapidly would mean more people could get the correct treatment for the lymphoma which has caused their HLH. They could receive the correct treatment sooner. Earlier diagnosis and treatment could improve survival for these patients.
CONDITIONS
Official Title
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Informed consent
- Age 18 years or older
- Clinically confirmed haemophagocytic lymphohistiocytosis (HLH)
- High dose steroids and/or systemic anti-cancer therapy for less than 72 hours for current HLH episode (anakinra is not considered systemic anti-cancer therapy)
- Prior steroid use longer than 14 days at time of consent is allowed
- Patients with recurrent HLH may participate
- Patients known to have or have relapsed lymphoma may participate
You will not qualify if you...
- Known cause of HLH due to a non-malignant condition
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nottingham Univeristy Hospitals NHS Trust
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here